Here, we have used a highly sensitive functional TP53 assay, which not only determines the functional impact of TP53 mutations, but also explores other dysfunctions, such as splicing defects [18], to analyze a group of breast cancer patients treated with a neoadjuvant dose-intense chemotherapy regimen. Here, TP53 is linked to breast cancer.